GW Pharmaceuticals PLC GWPH, +2.62% said late Monday that it had a positive phase-three trial result for its Epidiolex drug. GW stock rose more than 7% in after-hours trading. Epidiolex is a drug that contains cannabidiol, or CBD, a compound found in cannabis plants. The drug is an anti-epilepsy medication and the phase-three trial was performed on 224 patients in six countries. GW said it was the fifth consecutive positive trial for Epidiolex. GW stock has gained 28% in the past year, as the S&P 500 index SPX, -0.45% rose 11%.
Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.
Recent Comments